Erlene Seymour

836 total citations
31 papers, 304 citations indexed

About

Erlene Seymour is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Erlene Seymour has authored 31 papers receiving a total of 304 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 9 papers in Oncology. Recurrent topics in Erlene Seymour's work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and Economic and Financial Impacts of Cancer (8 papers). Erlene Seymour is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (10 papers) and Economic and Financial Impacts of Cancer (8 papers). Erlene Seymour collaborates with scholars based in United States, United Kingdom and Spain. Erlene Seymour's co-authors include Sami N. Malek, Kerby Shedden, Kamlai Saiya-Cork, Julie J. Ruterbusch, Brian Parkin, Nisar A. Amin, Cheng Li, Charles A. Schiffer, Peter Ouillette and Jennifer Beebe‐Dimmer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Erlene Seymour

26 papers receiving 302 citations

Peers

Erlene Seymour
Martin Skarzynski United States
Jonathan Moreira United States
Lokanatha Dasappa India
Bachar Samra United States
Jennifer L. Cultrera United States
Andrea Patriarca Italy
Esther N. Oliva Italy
Blanche H. Mavromatis United States
Huiqiang Huang China
Limei Poon Singapore
Martin Skarzynski United States
Erlene Seymour
Citations per year, relative to Erlene Seymour Erlene Seymour (= 1×) peers Martin Skarzynski

Countries citing papers authored by Erlene Seymour

Since Specialization
Citations

This map shows the geographic impact of Erlene Seymour's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erlene Seymour with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erlene Seymour more than expected).

Fields of papers citing papers by Erlene Seymour

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erlene Seymour. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erlene Seymour. The network helps show where Erlene Seymour may publish in the future.

Co-authorship network of co-authors of Erlene Seymour

This figure shows the co-authorship network connecting the top 25 collaborators of Erlene Seymour. A scholar is included among the top collaborators of Erlene Seymour based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erlene Seymour. Erlene Seymour is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Abrisqueta, Pau, Eva González‐Barca, Carlos Panizo, et al.. (2024). Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. The Lancet Haematology. 11(2). e136–e146. 7 indexed citations
4.
Goyal, Gaurav, Amy J. Davidoff, Scott F. Huntington, et al.. (2023). The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open. 6(6). e2316642–e2316642. 5 indexed citations
5.
6.
Guadamuz, Jenny S., Ghulam Rehman Mohyuddin, Brian C.‐H. Chiu, et al.. (2022). Abstract 3669: Racial/ethnic disparities in treatment with bone-modifying agents among newly diagnosed multiple myeloma patients. Cancer Research. 82(12_Supplement). 3669–3669.
7.
Hamel, Lauren M., David W. Dougherty, Theresa A. Hastert, et al.. (2021). The DISCO App: A pilot test of a multi-level intervention to reduce the financial burden of cancer through improved cost communication. SHILAP Revista de lepidopterología. 1. 100002–100002. 12 indexed citations
8.
Diefenbach, Catherine, Pau Abrisqueta, Eva González‐Barca, et al.. (2021). Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.. Journal of Clinical Oncology. 39(15_suppl). 7512–7512. 8 indexed citations
9.
Seymour, Erlene, Julie J. Ruterbusch, Aaron N. Winn, et al.. (2020). The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States. Cancer. 127(1). 93–102. 4 indexed citations
10.
Seymour, Erlene, Jonas A. de Souza, & A. Mark Fendrick. (2020). Incorporating Value-Based Care Into Oncology. The Cancer Journal. 26(4). 311–322. 9 indexed citations
11.
Patel, Krish, Michael B. Maris, Bruce D. Cheson, et al.. (2020). Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma.. Journal of Clinical Oncology. 38(15_suppl). 3030–3030. 7 indexed citations
12.
Seymour, Erlene, Yiwei Li, Amro Aboukameel, et al.. (2020). Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study. Blood. 136(Supplement 1). 11–12. 1 indexed citations
13.
Budde, Lihua E., Sunil Babu, Izidore S. Lossos, et al.. (2019). ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL). Hematological Oncology. 37(S2). 564–566. 1 indexed citations
14.
Zarins, Katie R., Julie J. Ruterbusch, Patravoot Vatanasapt, et al.. (2019). Increasing incidence of Epstein‐Barr virus–related nasopharyngeal carcinoma in the United States. Cancer. 126(1). 121–130. 41 indexed citations
15.
Rogers, Kerry A., Lai Wei, Seema A. Bhat, et al.. (2019). A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia. Blood. 134(Supplement_1). 3049–3049. 2 indexed citations
16.
Seymour, Erlene, Julie J. Ruterbusch, Jennifer Beebe‐Dimmer, & Charles A. Schiffer. (2018). Real‐world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis. Cancer. 125(1). 135–143. 24 indexed citations
17.
Polk, Avery, Ye Lu, Tianjiao Wang, et al.. (2016). Colony-Stimulating Factor-1 Receptor Is Required for Nurse-like Cell Survival in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 22(24). 6118–6128. 38 indexed citations
18.
Amin, Nisar A., Erlene Seymour, Kamlai Saiya-Cork, et al.. (2016). A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 22(17). 4525–4535. 52 indexed citations
19.
Palomba, M. Lia, Carly G.K. Ziegler, Jesse Cotari, et al.. (2014). Multidimensional Single-Cell Analysis of BCR Signaling Reveals Proximal Activation Defect As a Hallmark of Chronic Lymphocytic Leukemia B Cells. PLoS ONE. 9(1). e79987–e79987. 10 indexed citations
20.
Ouillette, Peter, Kamlai Saiya-Cork, Erlene Seymour, et al.. (2013). Clonal Evolution, Genomic Drivers, and Effects of Therapy in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 19(11). 2893–2904. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin Skarzynski Breakdown of academic impact, for papers by Jonathan Moreira Breakdown of academic impact, for papers by Lokanatha Dasappa Breakdown of academic impact, for papers by Bachar Samra Breakdown of academic impact, for papers by Jennifer L. Cultrera Breakdown of academic impact, for papers by Andrea Patriarca Breakdown of academic impact, for papers by Esther N. Oliva Breakdown of academic impact, for papers by Blanche H. Mavromatis Breakdown of academic impact, for papers by Huiqiang Huang Breakdown of academic impact, for papers by Limei Poon
Rankless by CCL
2026